BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/8/2022 2:31:10 AM | Browse: 863 | Download: 2388
Publication Name World Journal of Diabetes
Manuscript ID 74740
Country Taiwan
ISSN 1948-9358 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Endocrinology & Metabolism
Manuscript Type Retrospective Study
Article Title Immediate-release tofacitinib reduces insulin resistance in non-diabetic active rheumatoid arthritis patients: A single-center retrospective study
Manuscript Source Invited Manuscript
All Author List Chrong-Reen Wang and Hung-Wen Tsai
ORCID
Author(s) ORCID Number
Chrong-Reen Wang http://orcid.org/0000-0001-9881-7024
Hung-Wen Tsai http://orcid.org/0000-0001-9223-2535
Funding Agency and Grant Number
Corresponding Author Chrong-Reen Wang, MD, PhD, Full Professor, Department of Internal Medicine, National Cheng Kung University Hospital, No. 138 Sheng-Li Road, Tainan 70403, Taiwan. wangcr@mail.ncku.edu.tw
Key Words Insulin resistance; Rheumatoid arthritis; Diabetes mellitus; Tofacitinib; Janus kinase inhibitor
Core Tip An increased risk of insulin resistance (IR) has been identified in rheumatoid arthritis (RA), a chronic inflammatory disorder with elevated levels of pathogenic cytokines. In addition to controlling RA activity, biologics targeting proinflammatory cytokines have been shown to reduce IR, while it remains to be elucidated whether Janus kinase inhibitor therapy can cause IR reduction in such patients. This retrospective study carried out in non-diabetic active RA patients classified into high-IR and low-IR groups before tofacitinib (TOF) therapy demonstrated reduced IR by 24 wk of TOF treatment in the active RA patients with high baseline IR status.
Publish Date 2022-06-08 02:31
Citation Wang CR, Tsai HW. Immediate-release tofacitinib reduces insulin resistance in non-diabetic active rheumatoid arthritis patients: A single-center retrospective study. World J Diabetes 2022; 13(6): 454-465
URL https://www.wjgnet.com/1948-9358/full/v13/i6/454.htm
DOI https://dx.doi.org/10.4239/wjd.v13.i6.454
Full Article (PDF) WJD-13-454.pdf
Full Article (Word) WJD-13-454.docx